OrthoPediatrics (KIDS) Competitors

Pulse Biosciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Pulse Biosciences' return on equity.

In the previous week, OrthoPediatrics had 7 more articles in the media than Pulse Biosciences. MarketBeat recorded 13 mentions for OrthoPediatrics and 6 mentions for Pulse Biosciences. OrthoPediatrics' average media sentiment score of 0.49 beat Pulse Biosciences' score of 0.47 indicating that OrthoPediatrics is being referred to more favorably in the media.

OrthoPediatrics has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

OrthoPediatrics presently has a consensus price target of $24.44, indicating a potential upside of 43.45%. Pulse Biosciences has a consensus price target of $30.00, indicating a potential upside of 60.86%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than OrthoPediatrics.

OrthoPediatrics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by insiders. Comparatively, 74.6% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

OrthoPediatrics has a net margin of -16.31% compared to NovoCure's net margin of -25.66%. OrthoPediatrics' return on equity of -7.01% beat NovoCure's return on equity.

In the previous week, NovoCure had 14 more articles in the media than OrthoPediatrics. MarketBeat recorded 27 mentions for NovoCure and 13 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.49 beat NovoCure's score of 0.03 indicating that OrthoPediatrics is being referred to more favorably in the news media.

OrthoPediatrics has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

NovoCure currently has a consensus price target of $27.29, indicating a potential upside of 71.82%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 43.45%. Given NovoCure's higher possible upside, equities research analysts plainly believe NovoCure is more favorable than OrthoPediatrics.

NovoCure has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, OrthoPediatrics had 9 more articles in the media than Enovis. MarketBeat recorded 13 mentions for OrthoPediatrics and 4 mentions for Enovis. OrthoPediatrics' average media sentiment score of 0.49 beat Enovis' score of 0.17 indicating that OrthoPediatrics is being referred to more favorably in the news media.

OrthoPediatrics has a net margin of -16.31% compared to Enovis' net margin of -52.69%. Enovis' return on equity of 8.74% beat OrthoPediatrics' return on equity.

98.5% of Enovis shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OrthoPediatrics has lower revenue, but higher earnings than Enovis. OrthoPediatrics is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Enovis has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Enovis currently has a consensus price target of $47.43, indicating a potential upside of 96.72%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 43.45%. Given Enovis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Enovis is more favorable than OrthoPediatrics.

In the previous week, Butterfly Network had 6 more articles in the media than OrthoPediatrics. MarketBeat recorded 19 mentions for Butterfly Network and 13 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.49 beat Butterfly Network's score of 0.46 indicating that OrthoPediatrics is being referred to more favorably in the news media.

OrthoPediatrics has a net margin of -16.31% compared to Butterfly Network's net margin of -73.63%. OrthoPediatrics' return on equity of -7.01% beat Butterfly Network's return on equity.

OrthoPediatrics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 25.2% of Butterfly Network shares are held by company insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Butterfly Network currently has a consensus price target of $5.56, indicating a potential upside of 15.40%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 43.45%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts plainly believe OrthoPediatrics is more favorable than Butterfly Network.

Butterfly Network has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.